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Two previously published reports provided guidelines for
managing the pharmacological interactions that can result
when patients are treated with protease inhibitors (PIs) or
non-nucleoside reverse transcriptase inhibitors (NNRTIs)
for human immunodeficiency virus (HIV) infection together
with rifamycins for tuberculosis (TB).1,2 This article presents
current data pertaining to interactions between these
agents, with recommendations for their use from a group
of Centers for Disease Control (CDC) scientists and outside
expert consultants; these include initial recommendations
for the PIs lopinavir/ritonavir, atazanavir, and fos-
amprenavir (a phosphate ester prodrug of amprenavir).
The principal locus of these drug-drug interactions is the
cytochrome P450 (CYP) system in the intestinal wall and
liver, specifically the iso-enzyme CYP3A4.3 Rifamycins are
antituberculosis agents that induce the activity of CYP3A4
and may thereby substantially decrease serum
concentrations of PIs and NNRTIs.  The available rifamycins
differ in potency as CYP3A4 inducers, with rifampin
(rifampicin) being the most potent, rifapentine being
intermediate, and rifabutin being the least potent inducer.4
As such, rifabutin can be safely used with most PIs and
NNRTIs, except saquinavir and delavirdine (see Table II).
Unlike rifampin (rifampicin) and rifapentine, however,
rifabutin is also a substrate for CYP3A4; its serum
concentration is therefore affected by the degree to which
CYP3A4 is inhibited or induced by PIs and NNRTIs.
Rifapentine, a long-acting rifamycin, is not recommended
for the treatment of TB in HIV-infected persons because of
its association with acquired rifamycin resistance in such
patients.5
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Among the available antiretroviral (ARV) agents, ritonavir
has the highest potency in inhibiting CYP3A4, a quality that
increases the serum concentrations of other co-
administered PIs,6 although it can also increase
concentrations of rifabutin and a rifabutin metabolite to
toxic levels.7
Initial guidance from the CDC stated that use of rifampin
(rifampicin) was contraindicated for persons taking NNRTIs
and PIs.1 Subsequent data, however, have supported the
use of rifampin (rifampicin) with certain combinations of
ARV agents.  These include:
■ ritonavir with nucleoside/tide reverse transcriptase
inhibitors (NRTIs)8
■ efavirenz with NRTIs.9-11
Alternative, less supported, ARV combinations for use with
rifampin (rifampicin) include: 
■ ritonavir (400 mg twice daily) and saquinavir (400 mg
twice daily) with NRTIs12
■ ritonavir  (400 mg twice daily) and lopinavir (400 mg
twice daily) with NRTIs (when the current co-
formulated lopinavir/ritonavir combination is
supplemented with additional ritonavir, see Table I)13
■ nevirapine with NRTIs14-17 (and Boehringer Ingelheim,
Viramune Product information, 2002)
■ triple NRTIs.1,2
It is noteworthy that the ritonavir dose typically used for
pharmaco-enhancement of co-administered PIs (i.e. 100
mg or 200 mg twice daily),19 though less likely to produce
adverse events than higher doses, still results in net
CYP3A4 induction when used with rifampin (rifampicin)13
(and BMS Virology, Reyataz package insert, 2003). Data are
lacking for other PIs co-administered with rifampin
(rifampicin) and ritonavir 400 mg twice daily.  The use of
nevirapine and NRTIs with rifampin (rifampicin) is of
particular importance in countries with limited resources
where rifabutin may not be available, and for pregnant
patients, in whom efavirenz cannot be used.  Despite
pharmacokinetic data showing a significant reduction in
nevirapine concentrations when co-administered with
rifampin (rifampicin),14-17 two small studies demonstrated a
favourable clinical and virological response.16,18
Nonetheless, until additional data are available, rifampin
(rifampicin)- and nevirapine-containing ARV regimens
RIFAMPIN (RIFAMPICIN) AND ANTIRETROVIRAL
THERAPY (TABLE I)
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should only be used when no other options are available
and close clinical and virological monitoring can be
performed.
Rifabutin can be used with most PIs, including atazanavir
and fos-amprenavir, provided the dose of rifabutin is
reduced (Abbott Laboratories, Kaletra package insert, 2003
revised). Use of rifabutin with saquinavir alone is not
advised given the significant decrease in saquinavir
concentration; however, rifabutin may be used with
saquinavir if co-administered with ritonavir.  Other PI/
ritonavir combinations, including lopinavir/ritonavir, can be
safely co-administered with rifabutin as long as the dose of
rifabutin is decreased.20 Conversely, as a CYP3A4 inducer
efavirenz can reduce concentrations of rifabutin,
necessitating an increase in the dose of rifabutin.21
RIFABUTIN AND ANTIRETROVIRAL THERAPY 
(TABLE II)
Antiretroviral Rifampin (rifampicin)
Single PIs dose change dose change* Comments
Ritonavir None None Ritonavir AUC  ↓ by 35%; no change in
(600 mg/d) rifampin (rifampicin) concentration
Amprenavir Rifampin (rifampicin) and amprenavir should Amprenavir AUC ↓ by 82%, Cmin ↓ by 92%
not be used together
fos-amprenavir Rifampin (rifampicin) and fos-amprenavir See amprenavir
should not be used together
Atazanavir Rifampin (rifampicin) and atazanavir should Interaction studies not performed, but marked 
not be used together decrease in atazanavir concentrations predicted
Indinavir Rifampin (rifampicin) and indinavir should Indinavir AUC ↓ 89%
not be used together
Nelfinavir Rifampin (rifampicin) and nelfinavir should Nelfinavir AUC ↓ 82%
not be used together
Saquinavir Rifampin (rifampicin) and saquinavir should Saquinavir AUC ↓ 84%
not be used together
Recommended change Recommended change  
in dose of in dose of rifampin 
Dual PI combinations antiretroviral drug (rifampicin) Comments
Saquinavir / ritonavir Saquinavir 400 mg + None Limited clinical experience12
ritonavir 400 mg (600 mg/day)
twice/day
Phamaco-augmented lopinavir/ritonavir Lopinavir/ritonavir None Limited clinical experience. Increased
(Kaletra®) (Kaletra®) – 3 capsules (600 mg/day) hepatotoxicity from ritonavir is likely13
Note: Additional ritonavir required + 300 mg ritonavir 
twice/day
Lopinavir/ritonavir (Kaletra®) Rifampin (rifampicin) and lopinavir/ritonavir Lopinavir AUC ↓ by 75 % & Cmin ↓ by 99% 
(Kaletra®) should not be used together.  If 
Kaletra® is used with rifampin (rifampicin), 
additional ritonavir is required (see above)
Non-nucleoside reverse  Recommended change Recommended change
transcriptase inhibitors in dose of in dose of rifampin
antiretroviral drug (rifampicin) Comments
Efavirenz ↑ to 800 mg/day† None Efavirenz AUC ↓ by 22%; no change in rifampin
(600 mg/day) (rifampicin) concentration 
Nevirapine 200 mg twice daily None Nevirapine AUC ↓ 37% - 58% and Cmin ↓ 68% with
( 600 mg/day) 200 mg 2x/day dose14-16 (and Boehringer Ingelheim 
Viramune product information).  Limited, though 
favorable data for efficacy of 200 mg BID dose, 
although should only be used if no other options 
exist and clinical and virological monitoring 
possible.16,17 May consider 300 mg BID only if close 
biochemical monitoring feasible; however, no 
clinical, pharmacokinetic, or safety data available for
300 mg BID dose
Delavirdine Rifampin (rifampicin) and delavirdine should Delavirdine AUC ↓ by 95%
not be used together
*References proved for combinations with either inconclusive or limited data.
†May ↓ to 600 mg/day if  800 mg dose not easily tolerated.
TABLE I.  RECOMMENDATIONS FOR CO-ADMINISTERING PROTEASE INHIBITORS AND NON-NUCLEOSIDE REVERSE TRANSCRIPTASE
INHIBITORS WITH RIFAMPIN (RIFAMPICIN) — UNITED STATES, 2004*
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Further study is needed regarding the co-administration of
other complex ARV combinations (e.g. the concurrent use
of CYP3A4 inducer and inhibitor, such as efavirenz and a PI)
with rifabutin and rifampin (rifampicin).  One observational
study found that the use of rifabutin with such complex
ARV regimens was associated with low serum
concentrations of rifabutin, particularly when the rifabutin
dose was reduced to 150 mg twice weekly for use with
ritonavir-containing regimens.21
The NRTIs, which include zidovudine, didanosine,
zalcitabine, stavudine, lamivudine, abacavir and
emtricitabine, are not metabolised by CYP3A4, so NRTIs and
rifampicins may be co-administered without dose
adjustments.  However, ARV therapy consisting exclusively
of NRTIs appears to have reduced potency compared with
regimens that contain either a PI or an NNRTI, and current
guidelines recommend NRTI-based regimens only if PI-
based or NNRTI-based regimens cannot be used.22 As with
NRTIs, in vitro and pharmacokinetic data suggest that
CYP3A4 is not involved in the metabolism of either the
NRTI tenofovir or the fusion inhibitor enfuvirtide, and each
is therefore considered safe to use with any of the
rifamycins23 (and Gilead Sciences Inc., Viread package
insert, 2002).
Rifamycin resistance has developed during the treatment
of TB in HIV-infected persons, and has been associated with
all rifamycins, particularly with highly intermittent
administration (once or twice weekly).  Rifapentine, which
can be administered once a week, is not recommended for
HIV-infected patients because of their risk of developing
OTHER DRUG INTERACTION ISSUES
Single protease Antiretroviral dose Rifabutin dose 
inhibitors change change* Comments
Amprenavir None ↓ to 150 mg/day Rifabutin AUC ↑ by 193%; no change in
or 300 mg 3x/week amprenavir concentration.
fos-amprenavir None ↓ to 150 mg/day Comparable to amprenavir.
or 300 mg 3x/week
Atazanavir None ↓ to 150 mg every other day 
or 150 mg 3x/week† Rifabutin AUC ↑ by 250%
Indinavir ↑ to 1 000 mg q 8 h ↓ to 150 mg/day
or 300 mg 3x/week Rifabutin AUC ↑ by 204%; 
indinavir AUC ↓ by 32%.
Nelfinavir ↑ to 1 000 mg q 8 h ↓ to 150 mg/day
or 300 mg 3x/week Rifabutin AUC ↑ by 207%; 
nelfinavir AUC ↓ by 32%
Ritonavir None ↓ to 150 mg every other day Rifabutin AUC ↑ by 430%; no change in
or 150 mg 3x/week ritonavir concentration
Saquinavir Rifabutin and saquinavir should not be used together Saquinavir AUC ↓ by 43%
Dual protease inhibitor Antiretroviral dose Rifabutin dose Comments
combinations change change*
Lopinavir / ritonavir None ↓ to 150 mg every other day Rifabutin AUC ↑ by 303%;
(Kaletra™) or 150 mg 3x/week 25-O-des-acetyl rifabutin
AUC ↑ by 47.5-fold
Ritonavir (any dose) with None ↓ to 150 mg every other day
saquinavir, indinavir, or 150 mg 3x/week
amprenavir, fos-amprenavir, 
or atazanavir
Non-nucleoside reverse Antiretroviral dose Rifabutin dose
transcriptase inhibitors change change† Comments
Efavirenz None ↑ to 450 mg/day or 600 mg Rifabutin AUC ↓ by 38%
3x/week Effect of efavirenz + protease inhibitor (s)
on rifabutin concentration has not been 
studied
Nevirapine None 300 mg/day or 300 mg 3x/week Rifabutin and nevirapine AUC not 
significantly changed
Delavirdine Rifabutin and delavirdine should not be used together Delavirdine AUC ↓ by 80%; 
rifabutin AUC ↑ by 100%
*If CD4 count is greater than 100  cells/µl, may consider twice weekly administration of rifabutin with  amprenavir, fos-amprenavir, indinavir, nelfinavir, efavirenz, and nevirapine.
†Recommendation as per package insert.
TABLE II.  RECOMMENDATIONS FOR CO-ADMINISTERING PROTEASE INHIBITORS AND NON-NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITORS WITH RIFABUTIN — UNITED STATES, 2004
ACQUIRED RIFAMYCIN RESISTANCE
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rifamycin resistance.5 In addition, rifamycin resistance has
developed in patients who have advanced HIV disease (i.e.
CD4 count < 100 cells/µl) and are receiving rifampin
(rifampicin) or rifabutin twice weekly.24-26 To prevent
acquired rifamycin resistance in persons with advanced HIV
infection and TB, more frequent therapy (thrice weekly or
daily) with either rifampin (rifampicin)- or rifabutin-based
TB regimens is recommended.
As new ARV agents and additional pharmacokinetic data
become available, recommendations for the use of these
agents during the treatment of TB are likely to be revised
and updated.  More general information on ARV drug
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